Screener
Boston Scientific BSX Cardiovascular — Operating Income (Loss), Adjusted
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept bsx:OperatingIncomeLossAdjusted.
The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 6:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885725-26-000033
| (in millions, except percentages) | Med Surg | % of Net Sales | Cardiovascular | % of Net Sales | Total |
|---|---|---|---|---|---|
| Selling, general and administrative expenses | 557 | 32.8% | 959 | 27.4% | |
| Research and development expenses | 127 | 7.5% | 343 | 9.8% | |
| Other segment items(1) | 5 | 0.3% | 7 | 0.2% | |
| Segment operating income(2) | 533 | 31.3% | 1,125 | 32.1% | 1,658 |
| Unallocated amounts: | |||||
| Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments | (199) | ||||
| Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs | (126) | ||||
| Amortization expense | (232) |
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Boston Scientific's cardiovascular — operating income (loss), adjusted?
- Boston Scientific (BSX) reported cardiovascular — operating income (loss), adjusted of $1.13B in Q1 2026.
- How has Boston Scientific's cardiovascular — operating income (loss), adjusted changed year-over-year?
- Boston Scientific's cardiovascular — operating income (loss), adjusted increased by 5.3% year-over-year, from $1.07B to $1.13B.
- What is the long-term trend for Boston Scientific's cardiovascular — operating income (loss), adjusted?
- Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — operating income (loss), adjusted has grown at a 34.3% compound annual growth rate (CAGR), from $1.78B to $4.32B.
- What does cardiovascular — operating income (loss), adjusted mean?
- This metric represents the profitability of the cardiovascular segment after excluding non-recurring or non-operational charges. It provides a clear view of the underlying earnings power of the cardiovascular medical device business.
Ask your AI about Boston Scientific's cardiovascular — operating income (loss), adjusted.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude